Inclusion Criteria:

- Patients may have clinically documented primary malignant glioma for which
re-resection is clinically indicated; in this instance, previous pathology slides
will be reviewed by University of Washington Medical Center (UWMC) Neuropathology
prior to surgery; alternatively, patients may have imaging studies (magnetic
resonance imaging [MRI] and /or computed tomography [CT] scans), which are highly
indicative of a new malignant glioma, for which surgical resection is clinically
warranted; the anticipated histology at resection should include: glioblastoma,
gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic
oligoastrocytoma (mixed glioma)

- Prior therapy is not a consideration in protocol entry; patients with recurrence of
known malignant gliomas are eligible following UWMC neuropathology slide review

- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

- Life expectancy is not a consideration for protocol entry

- Patients must have normal organ and marrow function as defined below:

- Leukocytes >= 3,000/uL

- Absolute neutrophil count >= 1,500/uL

- Platelets >= 100,000/uL

- Total bilirubin within normal institutional limits

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT])
=< 2.5 X institutional upper limit of normal

- Creatinine within normal institutional limits OR creatinine clearance >= 60
mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

- The effects of ALA on the developing human fetus are unknown; for this reason, women
of child-bearing potential and men must agree to use adequate contraception (hormonal
or barrier method of birth control; abstinence) prior to study entry and for the
duration of study participation; should a woman become pregnant or suspect she is
pregnant while participating in this study, she should inform her treating physician
immediately

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Prior therapy is not an exclusion criterion

- Patients may not be receiving any other investigational agents

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to ALA

- Personal or family history of porphyrias

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study because ALA is of unknown teratogenic or
abortifacient effects; because there is an unknown but potential risk for adverse
events in nursing infants secondary to treatment of the mother with ALA,
breastfeeding should be discontinued if the mother is treated with ALA